Pilot Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin (Boca HBVIg) Used in Combination With Lamivudine for Patients With Hepatitis B Virus (HBV) Associated Liver Disease Undergoing Liver Transplantation

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Biotest Pharmaceuticals Corporation
ClinicalTrials.gov Identifier:
NCT01421212
First received: August 18, 2011
Last updated: August 19, 2011
Last verified: August 2011

August 18, 2011
August 19, 2011
November 1999
February 2002   (final data collection date for primary outcome measure)
  • Number of hepatitis B virus positive liver transplant recipients with no hepatitis B virus recurrence after liver transplantation. [ Designated as safety issue: No ]
  • Number of participants who maintain a protective trough titer of anti hepatitis B antibodies beginning at 12 weeks post liver transplantation. [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01421212 on ClinicalTrials.gov Archive Site
Change in anti hepatitis B antibodies levels with administration of Boca hepatitis B immune globulin concomitantly with Lamivudine. [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Pilot Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin (Boca HBVIg) Used in Combination With Lamivudine for Patients With Hepatitis B Virus (HBV) Associated Liver Disease Undergoing Liver Transplantation
Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin Used in Combination With Lamivudine

The purpose of this study is to find the best monthly dose schedule for the new Hepatitis Immune Globulin (Boca HBVIg, a study drug) when used in combination with an antiviral agent Lamivudine after liver transplantation. Boca HBVIg will be given along with Lamivudine to prevent hepatitis B reinfection following liver transplantation in patients with end stage liver failure due to hepatitis B infection.

Not Provided
Interventional
Phase 1
Phase 2
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Hepatitis B Virus (HBV) Associated Liver Disease.
Biological: Hepatitis B Immune Globulin (Boca HBVIg)

Phase I (12 weeks): Intravenous Boca HBVIg 10,000 IU administered intraoperatively during the anhepatic phase, following reperfusion, daily on days 1-7, once during week 4 and once during week 8 (total of 11 doses).

Phase II (24 weeks): Starting at 12 weeks post liver transplantation, Boca HBVIg will be reduced to 5,000 IU given intravenously on a monthly basis for patients who had an anti-HBs trough titer greater than or equal to 500 IU/L at 8 weeks without the need for additional Boca HBVIg doses. Patients with an 8 week trough level less than 500 IU/L will receive 10,000 IU Boca HBVIg every 4 weeks for the remainder of the study.

Other Names:
  • Nabi-HB
  • HepaGam B
  • Hepatitis B Immune Globulin
  • HBIG
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
February 2002
February 2002   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Be 18 years old or greater, either male or female, of any ethnic background.
  • Be positive for HBsAg. Patients may be either positive or negative for anti-HDV, HBeAg, and HBV DNA (non-PCR assay).
  • Be diagnosed with HBV-induced liver disease including either:
  • HBsAg positive cirrhosis, or
  • HBsAg positive and presence of hepatocellular carcinoma (HCC) with no evidence of vascular invasion or extrahepatic spread, and either:
  • a single tumor no larger than 5 cm in diameter, or
  • no more than three tumors, the largest of which is no greater than 3 cm in diameter.
  • Have received at least one dose of Lamivudine 100 mgs po qd prior to transplantation.
  • Fulfill UNOS minimal listing criteria.
  • Have received approval for liver transplantation at the respective participating center and are listed as Status 2 or 3 and felt to be within three months of liver transplantation.
  • If requiring retransplantation for primary graft nonfunction or hepatic artery thrombosis, retransplantation must take place within the first four weeks of the initial transplant with no evidence of recurrent hepatitis B.
  • Be able and willing to give written informed consent. In patients with Grade 3 or 4 hepatic encephalopathy, a legal guardian must be available to provide consent. In the case of a minor, a parent or guardian must provide consent.
  • If a woman of childbearing potential, have a negative serum beta HCG pregnancy test within 14 days prior to starting Lamivudine therapy and within 14 days prior to transplant and agree to practice contraception during the study (a total of 36 weeks).

Exclusion Criteria:

  • Eligible patients must not:
  • Require retransplantation for recurrent hepatitis B.
  • Have chronic hepatitis B liver disease with a history of breakthrough infection on Lamivudine
  • Have other causes of liver disease including chronic hepatitis C.
  • Have HCC and do not meet Inclusion Criterion #3, or who require systemic chemotherapy.
  • Be seropositive for HIV infection.
  • Be using experimental devices or receiving experimental drugs.
  • Be participating in any other clinical treatment trial with an investigational drug within 30 days prior to liver transplantation or plan to receive another investigational drug during this study.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01421212
Nabi-4204
No
Biotest Pharmaceuticals Corporation
Biotest Pharmaceuticals Corporation
Not Provided
Principal Investigator: Rolland C. Dickson, M.D. Mayo Clinic Jacksonville, FL
Principal Investigator: Norah A. Terrault, M.D., MPH University of California, San Francisco, CA
Principal Investigator: Donald Jensen, M.D. Rush-Presbyterian - St. Luke's Medical Center, Chicago, IL
Principal Investigator: Terence Angtuaco, M.D. Rush-Presbyterian - St. Luke's Medical Center, Chicago, IL
Principal Investigator: Patricia Sheiner, M.D. Mount Sinai Medical Center, New York, NY
Principal Investigator: Velimir A. Luketic, M.D. Virginia Commonwealth University, Richmond, VA
Principal Investigator: Michael Fried, M.D. University of North Carolina, Chapel Hill, NC
Principal Investigator: Robert S. Brown, M.D., MPH Columbia-Presbyterian Medical Center, New York, NY
Principal Investigator: Michael Ishitani, M.D. Rochester Methodist Hospital, Rochester, MN
Principal Investigator: Consuelo Soldevila-Pico, M.D. University of Florida
Principal Investigator: Anna Lok, M.D. University of Michigan, Ann Arbor, MI
Principal Investigator: Rajender Reddy, M.D. University of Miami, Miami, FL
Biotest Pharmaceuticals Corporation
August 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP